New cocktail of drugs takes on Hard-to-Treat prostate cancer
NCT ID NCT02861573
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to other cancer treatments can help men with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and no longer responds to hormone therapy. About 1,200 participants will receive one of several combination therapies, including pembrolizumab with olaparib, docetaxel, enzalutamide, or lenvatinib. The goal is to see if these combinations are safe and can shrink tumors or lower PSA levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) combined with other drugs like olaparib, docetaxel, enzalutamide, or lenvatinib
- What this could lead to
- If successful, this could offer new combination treatment options for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with many different drug combinations, so results are preliminary. Side effects from combining these powerful drugs could be significant, and not all combinations may prove effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out